Guangdong Taienkang Pharmaceutical Co. Ltd (301263) - Net Assets
Based on the latest financial reports, Guangdong Taienkang Pharmaceutical Co. Ltd (301263) has net assets worth CN¥1.77 Billion CNY (≈ $258.49 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.47 Billion ≈ $360.88 Million USD) and total liabilities (CN¥699.72 Million ≈ $102.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guangdong Taienkang Pharmaceutical Co. L (301263) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.77 Billion |
| % of Total Assets | 71.63% |
| Annual Growth Rate | 23.18% |
| 5-Year Change | 145.3% |
| 10-Year Change | N/A |
| Growth Volatility | 58.45 |
Guangdong Taienkang Pharmaceutical Co. Ltd - Net Assets Trend (2019–2025)
This chart illustrates how Guangdong Taienkang Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. See Guangdong Taienkang Pharmaceutical Co. L (301263) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Guangdong Taienkang Pharmaceutical Co. Ltd (2019–2025)
The table below shows the annual net assets of Guangdong Taienkang Pharmaceutical Co. Ltd from 2019 to 2025. For live valuation and market cap data, see 301263 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.74 Billion ≈ $254.79 Million |
-4.14% |
| 2024-12-31 | CN¥1.82 Billion ≈ $265.79 Million |
-0.71% |
| 2023-12-31 | CN¥1.83 Billion ≈ $267.70 Million |
-1.33% |
| 2022-12-31 | CN¥1.85 Billion ≈ $271.29 Million |
+161.19% |
| 2021-12-31 | CN¥709.81 Million ≈ $103.87 Million |
+20.38% |
| 2020-12-31 | CN¥589.63 Million ≈ $86.28 Million |
+18.30% |
| 2019-12-31 | CN¥498.40 Million ≈ $72.93 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Taienkang Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 98.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥327.17 Million | 19.58% |
| Other Components | CN¥1.34 Billion | 80.42% |
| Total Equity | CN¥1.67 Billion | 100.00% |
Guangdong Taienkang Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Guangdong Taienkang Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lier Chemical Co Ltd
SHE:002258
|
$1.52 Billion |
|
Bros Eastern Co Ltd
SHG:601339
|
$1.52 Billion |
|
Digiwin Software Co Ltd
SHE:300378
|
$1.52 Billion |
|
Zhongman Petro & Natural Gas
SHG:603619
|
$1.52 Billion |
|
Aveanna Healthcare Holdings Inc
NASDAQ:AVAH
|
$1.51 Billion |
|
Thai Union Group Public Company Limited
BK:TU-R
|
$1.51 Billion |
|
Lanzhou LS Heavy Equipment Co
SHG:603169
|
$1.51 Billion |
|
Tellhow Sci-Tech Co Ltd
SHG:600590
|
$1.51 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Taienkang Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,767,056,577 to 1,671,244,318, a change of -95,812,259 (-5.4%).
- Net income of 28,632,896 contributed positively to equity growth.
- Dividend payments of 93,579,759 reduced retained earnings.
- Other factors decreased equity by 30,865,396.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥28.63 Million | +1.71% |
| Dividends Paid | CN¥93.58 Million | -5.6% |
| Other Changes | CN¥-30.87 Million | -1.85% |
| Total Change | CN¥- | -5.42% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Taienkang Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.35x to 6.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.19 | CN¥20.27 | x |
| 2020-12-31 | CN¥1.85 | CN¥20.27 | x |
| 2021-12-31 | CN¥2.22 | CN¥20.27 | x |
| 2022-12-31 | CN¥3.63 | CN¥20.27 | x |
| 2023-12-31 | CN¥3.51 | CN¥20.27 | x |
| 2024-12-31 | CN¥4.15 | CN¥20.27 | x |
| 2025-12-31 | CN¥3.27 | CN¥20.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Taienkang Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.24%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.45x
- Recent ROE (1.71%) is below the historical average (11.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 11.06% | 11.06% | 0.73x | 1.37x | CN¥5.27 Million |
| 2020 | 27.27% | 22.68% | 0.85x | 1.42x | CN¥101.85 Million |
| 2021 | 16.91% | 18.37% | 0.69x | 1.33x | CN¥49.07 Million |
| 2022 | 9.42% | 22.29% | 0.38x | 1.10x | CN¥-10.80 Million |
| 2023 | 8.95% | 21.06% | 0.34x | 1.25x | CN¥-18.80 Million |
| 2024 | 6.12% | 15.01% | 0.31x | 1.31x | CN¥-68.49 Million |
| 2025 | 1.71% | 4.24% | 0.28x | 1.45x | CN¥-138.49 Million |
Industry Comparison
This section compares Guangdong Taienkang Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Taienkang Pharmaceutical Co. Ltd (301263) | CN¥1.77 Billion | 11.06% | 0.40x | $1.51 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Guangdong Taienkang Pharmaceutical Co. Ltd
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the… Read more